Osimertinib
EGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversitySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 81/ 100
Competitive context
30 Active assets in the EGFR Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gefetinib China Medical University Hospital | Phase 2/3 | BB |
Carboplatin Guangdong Provincial People's Hospital | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Sichuan Cancer Hospital and Research Institute | Phase 3 | B |
Cyclophosphamide Hideho Okada, MD, PhD | Phase 2 | B |
Panobinostat Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 3 | B |
View all 50 →
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →